Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Non Operating Income (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Non Operating Income for 15 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 188.14% year-over-year to -$2.2 million, compared with a TTM value of $10.2 million through Dec 2025, up 208.51%, and an annual FY2025 reading of $10.2 million, up 208.51% over the prior year.
  • Non Operating Income was -$2.2 million for Q4 2025 at Amicus Therapeutics, down from $10.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $13.6 million in Q3 2022 and bottomed at -$18.6 million in Q4 2022.
  • Average Non Operating Income over 5 years is -$690400.0, with a median of $31000.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 5652.74% in 2022, while the deepest fall reached 10730.23% in 2022.
  • Year by year, Non Operating Income stood at -$172000.0 in 2021, then tumbled by 10730.23% to -$18.6 million in 2022, then skyrocketed by 84.54% to -$2.9 million in 2023, then skyrocketed by 187.01% to $2.5 million in 2024, then tumbled by 188.14% to -$2.2 million in 2025.
  • Business Quant data shows Non Operating Income for FOLD at -$2.2 million in Q4 2025, $10.9 million in Q3 2025, and $1.0 million in Q2 2025.